{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:18Z","timestamp":1793371518621,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Bevacizumab-associated intestinal perforation and Fournier\u2019s gangrene have been reported separately; however, the potential contribution of residual anti-VEGF exposure prior to subsequent chemotherapy in previously irradiated pelvic tissue remains underrecognized. Radiotherapy causes fibrosis and microvascular injury, bevacizumab impairs healing, and irinotecan-induced diarrhea may exacerbate perforation risk. Deferring DRE, imaging, and surgical consultation in patients with unexplained perineal or buttock pain increases the risk. A 61-year-old man with rectal adenocarcinoma received neoadjuvant chemoradiotherapy followed by total mesorectal excision and ileostomy in March 2024. After adjuvant chemotherapy, surveillance in March 2025 revealed recurrence with pelvic invasion and liver\/lung metastases. He received eight cycles of XELOX plus bevacizumab, then bevacizumab maintenance, stopped on 4 March 2026 for rectal hemorrhage. This 22-day interval is shorter than the label-mandated 28-day hold and NCCN-recommended \u22656-week washout for surgery\u2014standards primarily addressing wound healing rather than chemotherapy sequencing. Five days after irinotecan initiation, grade 3 diarrhea developed. He was admitted on 13 April 2026 with diarrhea, left buttock pain; he received empirical ceftazidime plus moxifloxacin. On 14 April, DRE, imaging, and surgical consultation were deferred due to pain. By 18 April, septic shock developed with perineal necrosis and crepitus. CT confirmed Fournier\u2019s gangrene. Emergency debridement with abscess curettage and seton drainage was performed. Fecal diversion was declined. Antibiotics were escalated to meropenem then vancomycin after cultures grew\n                    <jats:italic>VSEfm<\/jats:italic>\n                    . He left the ICU but needed twice-daily dressing changes. Two weeks postoperatively, care shifted to palliation, and he died of multiorgan failure. This case raises the hypothesis that, in previously irradiated tissue, residual bevacizumab exposure at the time of subsequent irinotecan initiation\u2014exacerbated by irinotecan-induced diarrhea and pre-existing rectal mucosal damage\u2014may have contributed to rectal perforation and subsequent Fournier\u2019s gangrene. Notably, while bevacizumab and irinotecan are routinely combined, whether extrapolating surgical washout standards (\u22656 weeks) to anti-VEGF sequencing before high-mucosal-toxicity chemotherapy warrants prospective investigation. Unexplained perineal or buttock pain in such patients should trigger urgent clinical evaluation, including DRE when feasible, imaging, and early surgical consultation, to prevent diagnostic delay.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1942096","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:32:50Z","timestamp":1790224370000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: rectal perforation and Fournier's gangrene after irinotecan in a bevacizumab-exposed, previously irradiated patient"],"prefix":"10.3389","volume":"16","author":[{"given":"Libo","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Emeishan Hospital of Traditional Chinese Medicine","place":["Emeishan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery, Emeishan Hospital of Traditional Chinese Medicine","place":["Emeishan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.528","article-title":"Localised rectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Hofheinz","year":"2025","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.46","article-title":"Radiation enteropathy--pathogenesis, treatment and prevention","volume":"11","author":"Hauer-Jensen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"B7","volume-title":"Avastin (Bevacizumab) Prescribing Information","year":"2025"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.052","article-title":"Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study","volume":"48","author":"Kabbinavar","year":"2012","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1600673","article-title":"Necrotizing soft-tissue infections","volume":"377","author":"Stevens","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpsurg.2014.06.001","article-title":"Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes","volume":"51","author":"Hakkarainen","year":"2014","journal-title":"Curr Probl Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2000.01497.x","article-title":"Fournier's gangrene: a review of 1726 cases","volume":"87","author":"Eke","year":"2000","journal-title":"Br J Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2019.04.234","article-title":"ASGE guideline on the role of endoscopy for bleeding from chronic radiation proctopathy","volume":"90","author":"Lee","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-018-1401-4","article-title":"A fatal case of Fournier's gangrene during neoadjuvant radiotherapy for rectal cancer","volume":"195","author":"Klement","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"B15","article-title":"a case of Fournier's gangrene due to perforation of lower rectal cancer during chemotherapy","volume":"44","author":"Fukuhisa","year":"2017","journal-title":"Gan To Kagaku Ryoho"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2010.n.008","article-title":"Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer","volume":"9","author":"Gamboa","year":"2010","journal-title":"Clin Colorectal Cancer"},{"key":"B17","article-title":"Avastin (bevacizumab): pharmacovigilance safety communication\u2014necrotizing fasciitis","volume-title":"Avastin (Bevacizumab): Pharmacovigilance Safety Communication \u2013 Necrotizing Fasciitis","year":"2013"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3079-6","article-title":"Population pharmacokinetics of bevacizumab in cancer patients with external validation","volume":"78","author":"Han","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B19","article-title":"NCCN clinical practice guidelines in oncology: rectal cancer. Version 2.2026","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer","year":"2026"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-7-74","article-title":"Retroperitoneal abscess complicated with necrotizing fasciitis of the thigh in a patient with sigmoid colon cancer","volume":"7","author":"Takakura","year":"2009","journal-title":"World J Surg Oncol"},{"key":"B21","article-title":"two cases of Fournier's gangrene that occurred during chemotherapy for rectal cancer","volume":"44","author":"Koyama","year":"2017","journal-title":"Gan To Kagaku Ryoho"},{"key":"B22","article-title":"a case of Fournier's gangrene during second-line IRIS plus bevacizumab chemotherapy for rectal and anal canal cancer","volume":"49","author":"Imamura","year":"2022","journal-title":"Gan To Kagaku Ryoho"},{"key":"B23","first-page":"436","article-title":"Performance standards for antimicrobial susceptibility testing. 36th ed. CLSI document M100","volume-title":"Clinical and Laboratory Standards Institute","year":"2026"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3870\/j.issn.1004-0781.2021.08.012","article-title":"Analysis of distribution and drug resistance of pathogens in bloodstream infections in Sichuan antibiotics resistance monitoring network from 2016 to 2020","volume":"40","author":"Long","year":"2021","journal-title":"Herald Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/sur.2016.261","article-title":"The surgical infection society revised guidelines on the management of intra-abdominal infection","volume":"18","author":"Mazuski","year":"2017","journal-title":"Surg Infect (Larchmt)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1942096\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:33:18Z","timestamp":1790224398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1942096\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1942096"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1942096","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1942096"}}